JPMorgan Chase & Co. Has $37.04 Million Position in NewAmsterdam Pharma Company N.V. $NAMS

JPMorgan Chase & Co. lessened its position in NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) by 10.7% during the 3rd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 1,302,498 shares of the company’s stock after selling 156,399 shares during the period. JPMorgan Chase & Co. owned about 1.16% of NewAmsterdam Pharma worth $37,043,000 as of its most recent filing with the SEC.

Other large investors have also made changes to their positions in the company. Jennison Associates LLC lifted its holdings in NewAmsterdam Pharma by 42.5% during the 3rd quarter. Jennison Associates LLC now owns 4,198,554 shares of the company’s stock valued at $119,407,000 after purchasing an additional 1,252,451 shares during the last quarter. Adage Capital Partners GP L.L.C. raised its stake in shares of NewAmsterdam Pharma by 54.5% in the second quarter. Adage Capital Partners GP L.L.C. now owns 3,013,009 shares of the company’s stock valued at $54,566,000 after acquiring an additional 1,062,359 shares during the last quarter. Maverick Capital Ltd. boosted its holdings in shares of NewAmsterdam Pharma by 178.8% in the 2nd quarter. Maverick Capital Ltd. now owns 1,531,874 shares of the company’s stock worth $27,742,000 after acquiring an additional 982,405 shares in the last quarter. Frazier Life Sciences Management L.P. grew its position in NewAmsterdam Pharma by 3.0% during the 2nd quarter. Frazier Life Sciences Management L.P. now owns 16,607,074 shares of the company’s stock worth $300,754,000 after acquiring an additional 490,656 shares during the last quarter. Finally, Bank of New York Mellon Corp bought a new stake in NewAmsterdam Pharma during the 2nd quarter worth approximately $6,392,000. Institutional investors own 89.89% of the company’s stock.

NewAmsterdam Pharma Stock Up 3.4%

Shares of NAMS stock opened at $35.46 on Friday. The firm has a market cap of $4.08 billion, a price-to-earnings ratio of -20.50 and a beta of 0.06. NewAmsterdam Pharma Company N.V. has a 12 month low of $14.06 and a 12 month high of $42.00. The stock has a 50-day moving average price of $34.06 and a 200 day moving average price of $32.95.

NewAmsterdam Pharma (NASDAQ:NAMS) last issued its earnings results on Wednesday, February 18th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.40) by ($0.23). The business had revenue of $0.03 million during the quarter, compared to the consensus estimate of $0.92 million. NewAmsterdam Pharma had a negative net margin of 906.22% and a negative return on equity of 26.67%. Sell-side analysts predict that NewAmsterdam Pharma Company N.V. will post -1.75 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have commented on NAMS shares. Royal Bank Of Canada boosted their price objective on NewAmsterdam Pharma from $44.00 to $47.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 21st. Guggenheim lifted their price target on NewAmsterdam Pharma from $41.00 to $45.00 and gave the company a “buy” rating in a report on Thursday, February 19th. Stifel Nicolaus increased their price objective on shares of NewAmsterdam Pharma from $44.00 to $50.00 and gave the stock a “buy” rating in a report on Tuesday, December 16th. Wall Street Zen downgraded shares of NewAmsterdam Pharma from a “hold” rating to a “sell” rating in a research note on Saturday, February 21st. Finally, Leerink Partners reiterated an “outperform” rating and set a $55.00 target price on shares of NewAmsterdam Pharma in a research report on Tuesday, January 6th. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $46.55.

Insiders Place Their Bets

In related news, insider Johannes Jacob Piete Kastelein sold 45,481 shares of NewAmsterdam Pharma stock in a transaction on Friday, February 20th. The stock was sold at an average price of $35.31, for a total transaction of $1,605,934.11. Following the completion of the sale, the insider directly owned 53,500 shares of the company’s stock, valued at $1,889,085. The trade was a 45.95% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CAO Louise Frederika Kooij sold 32,612 shares of the company’s stock in a transaction dated Wednesday, January 28th. The shares were sold at an average price of $31.80, for a total value of $1,037,061.60. Following the completion of the sale, the chief accounting officer owned 24,353 shares of the company’s stock, valued at $774,425.40. This represents a 57.25% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 650,421 shares of company stock valued at $22,417,631. Company insiders own 20.84% of the company’s stock.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.